A formidable challenge requires a bold new approach

Driven to improve the lives of millions suffering from neurological diseases by developing therapies to increase neurogenesis.

A bold new approach

Bolden Therapeutics is developing first-in-class therapeutics to increase neurogenesis (the formation of new brain cells) and improve outcomes in neurological disease.

Bolden has established proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory in a proprietary mouse model targeting a novel and specific signaling pathway.

Bolden is developing multiple therapeutic modalities in parallel, leading with exon-skipping antisense oligonucleotides.

Target Indications

Due to the ​fundamental nature of neurogenesis, there are several potential clinical applications for neurogenesis-promoting therapies, such as those we aim to develop.

Alzheimer’s disease and related dementias
Stroke recovery
Treatment-resistant depression
Huntington’s disease
Parkinson’s disease
Brain injury
Cognitive impairment following chemotherapy or COVID-19 exposure

Resources

Neurogenesis is the formation of new neurons from neural stem cells (NSCs). It is an endogenous process that has been observed throughout life into advanced age. NSCs reside in at least two regions of the adult brain: the dentate gyrus of the hippocampus and the subventricular zone, which lines the lateral ventricles. Additional information about neurogenesis, Alzheimer's disease, and drug development can be found in our team’s publications.

Press Releases

June 29, 2022
Bolden Therapeutics Receives $497,500 SBIR Grant from The National Institute On Aging to Support Development Of Antisense Oligonucleotides to Promote Neurogenesis

CAMBRIDGE, MA. Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced being awarded a Small Business Innovative Research (SBIR) grant for $497,500 from the National Institute on Aging (NIA) of the National Institutes of Health.

SEPTEMBER 27, 2021
Bolden Therapeutics Receives $500,000 Small Business Grant from the National Institute on Aging

PROVIDENCE, RI & CAMBRIDGE, MA. Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for potential treatment ofCNS diseases such as Alzheimer’s disease, today announced receiving a $500,000 Phase I Small Business Technology Transfer (STTR) grant from the National Institute on Aging of the National Institutes of Health.

February 11, 2021
Bolden Therapeutics Receives Biogen-LabCentral ‘Golden Ticket’ Award

PROVIDENCE, RI. Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for potential treatment of CNS diseases such as Alzheimer’s and ischemic stroke, today announced being awarded the Biogen-LabCentral Golden Ticket.